Lewis, Sloan A.
Sureshchandra, Suhas
Zulu, Michael Z. http://orcid.org/0000-0002-3203-7866
Doratt, Brianna
Jankeel, Allen
Ibraim, Izabela Coimbra
Pinski, Amanda N.
Rhoades, Nicholas S. http://orcid.org/0000-0001-5650-4724
Curtis, Micaila http://orcid.org/0000-0002-8928-6855
Jiang, Xiwen
Tifrea, Delia
Zaldivar, Frank
Shen, Weining http://orcid.org/0000-0003-3137-1085
Edwards, Robert A.
Chow, Daniel
Cooper, Dan
Amin, Alpesh
Messaoudi, Ilhem http://orcid.org/0000-0003-3203-2405
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (1R01AI152258-01, R21AI143301-01A1, 1R01AI145910-01, T32 AI007319)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (NIH F31 A028704)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1 TR001414)
Article History
Received: 3 February 2021
Accepted: 13 September 2021
First Online: 28 October 2021
Competing interests
: A.A. reports serving as principal investigator or coinvestigator of clinical trials sponsored by the NIH/National Institute of Allergy and Infectious Diseases, NeuroRx Pharma, Pulmotect, Blade Therapeutics, Novartis, Takeda, Humanigen, Eli Lilly, PTC Therapeutics, Octapharma, Fulcrum Therapeutics and Alexion. He has served as speaker or consultant for Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Portola, Sunovion, Mylan/Theravance, Salix, Alexion, AstraZeneca, Novartis, Nabriva, Paratek, Bayer, Tetraphase, Achaogen LaJolla, Millenium, Ferring, PeraHealth, HeartRite, AseptiScope and Sprightly. The other authors declare no competing interests.
Free to read: This content has been made available to all.